ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2018
Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.BMC public health · 2020Pooled it
- Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci.Epidemiology and infection · 2020Pooled it
- Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults.Human vaccines & immunotherapeutics · 2026Trial
- Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.Human vaccines & immunotherapeutics · 2022Trial
- A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT).Human vaccines & immunotherapeutics · 2025Review
- Epidemiology of Bacterial Meningitis in the Lombardy Region, Italy, from 2014 to 2024: An Observational, Retrospective Study.Microorganisms · 2025Article
- Immunogenicity of primary and booster MenACWY-TT vaccination in older adults and the importance of IgM.NPJ vaccines · 2025Article
- Epidemiology and genetic diversity of invasive Neisseria meningitidis strains circulating in Portugal from 2003 to 2020.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study.Pediatric rheumatology online journal · 2023Observational
- Epidemiology, clinical features and outcome of adults with meningococcal meningitis: a 15-year prospective nationwide cohort study.The Lancet regional health. Europe · 2023Article
- Adolescent and parental decision-making for the MenACWY vaccination: influential predictors and parental-adolescent differences among households in the Netherlands.BMC public health · 2023Article
- Article
- Epidemiology and Clinical Burden of Meningococcal Disease in France: Scoping Review.Journal of clinical medicine · 2023Article
- Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.Human vaccines & immunotherapeutics · 2022Article
- Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Psychosocial and organizational barriers and facilitators of meningococcal vaccination (MenACWY) acceptance among adolescents and parents during the Covid-19 pandemic: a cross-sectional survey.BMC infectious diseases · 2022Article
- Pathogen- and Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands.Microorganisms · 2022Article
- Dynamics in public perceptions and media coverage during an ongoing outbreak of meningococcal W disease in the Netherlands.BMC public health · 2022Article
- Genomic surveillance of Neisseria meningitidis serogroup W in Portugal from 2003 to 2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Sex-Related Differences in the Immune Response to Meningococcal Vaccinations During Adolescence.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The annual incidence rate of serogroup W invasive meningococcal disease in the Netherlands increased from < 0.05/100,000 (n < 10) before 2015 to 0.5/100,000 (n = 80) in 2017. Most isolates (94%) belong to clonal complex 11. The incidence rate is highest among < 5 year-olds and 15-24 year-olds. The case fatality rate was 12% (17/138) in 2015-2017. From May 2018, MenACWY vaccination replaces MenC vaccination at age 14 months and from October 2018, 13-14 year-olds are offered MenACWY vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.